Health Care & Life Sciences » Biotechnology | Aquinox Pharmaceuticals Inc.

Aquinox Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
59.60
135.90
-
-
-
-
Gross Income
59.60
135.90
-
-
-
-
SG&A Expense
9,316.10
22,239.80
21,340.00
37,645.00
51,119.00
48,524
EBIT
9,375.70
22,375.70
21,340.00
37,645.00
51,119.00
23,524
Unusual Expense
961.60
849.20
52.00
81.00
-
10,400
Non Operating Income/Expense
303.80
254.90
369.00
56.00
58.00
780
Interest Expense
42.90
2,245.80
99.00
1.00
4.00
4
Pretax Income
8,734.40
24,027.20
21,860.00
37,002.00
50,183.00
31,585
Income Tax
5.00
0.20
-
-
-
-
Consolidated Net Income
8,729.40
23,821.30
21,860.00
37,002.00
50,183.00
31,585
Net Income
8,729.40
23,821.30
21,860.00
37,002.00
50,183.00
31,585
Net Income After Extraordinaries
8,729.40
23,821.30
21,860.00
37,002.00
50,183.00
31,585
Net Income Available to Common
8,729.40
23,821.30
21,860.00
37,002.00
50,183.00
31,585
EPS (Basic)
0.87
2.75
1.73
1.96
2.14
1.34
Basic Shares Outstanding
10,045.30
8,667.40
12,637.80
18,893.50
23,450.30
23,519.50
EPS (Diluted)
0.87
2.75
1.73
1.96
2.14
1.34
Diluted Shares Outstanding
10,045.30
8,667.40
12,637.80
18,893.50
23,450.30
23,519.50
EBITDA
9,316.10
22,239.80
-
-
-
-
Non-Operating Interest Income
26.30
-
-
619.00
998.00
1,563
Other After Tax Income (Expense)
-
205.70
-
-
-
-

About Aquinox Pharmaceuticals

View Profile
Address
887 Great Northern Way
Vancouver British Columbia V5T 4T5
Canada
Employees -
Website http://www.aqxpharma.com
Updated 07/08/2019
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.